“Paying it Forward: Why we need YOU to give blood" is an article by Dr. Jeannie Callum, a hospital-based transfusion specialist. Here she shares her real-life experience witnessing the impact of blood donation on patient lives. She provides some fascinating insight into blood transfusion, past and present, and emphasizes the need for male donors and why some donors may be safer for patients. This article is also being published in six parts on RED, our Research, Education and Discovery blog.
Current recommendations of the NAC indicate that the provision of CMV-seronegative and leukoreduced blood products is potentially required only in the setting of intrauterine transfusion. In October 2017, Canadian Blood Services will stop the testing donor blood for anti-CMV antibodies except for a small inventory of blood components tested for the sole purpose of intrauterine transfusion.
Decisions about blood safety need to take numerous factors into account, such as risks, benefits, costs, ethical issues, and stakeholder perspectives.
ABO has developed a unique framework to help blood service operators streamline the process and make responsible decisions that lead to the greatest good. Whether the blood safety decision to be made is small or large in scale, this framework can help to organize the process and to assure the quality of the information used to make the decision.
Canadian Blood Services delivers KnowledgeInfusion activities to disseminate research findings that are aligned with the goals of our organization in order to accelerate their uptake by the transfusion community. KnowledgeInfusion activities include Lunch&Learn webinars that are recorded and shared below.
Abnormal bleeding may result from defects in platelets, coagulation factors and/or blood vessels. Screening tests for coagulation factor abnormalities include the activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) / International Normalized Ratio (INR). Thrombocytopenia is the most common platelet defect. Qualitative platelet defects may also occur and, in some cases, may be associated with thrombocytopenia. In patients with platelet defects, bleeding time and/or closure times using the platelet function analyzer (PFA-100/200TM) may be prolonged. Vascular defects may be accompanied by joint hyperflexibility or skin laxity. Effective treatment of hemostatic disorders requires accurate diagnosis and special coagulation testing that may include coagulation factor assays, inhibitor assays, and platelet function tests. An algorithmic approach to diagnosis is beyond the scope of this review.
Apheresis involves the removal of whole blood from an individual and its separation into components. A specified component is retained and the remainder is returned to the individual. Therapeutic apheresis is used to treat patients with a variety of disorders and has become a relatively common treatment modality. The rationale and techniques for therapeutic apheresis, as well as the care of the apheresis patient, will be discussed in this chapter.